Hakon Hakonarson

This inventor holds 47 USPTO granted patents and 44 published patent applications, plus 10 CIPO patents and 24 EPO patents, primarily in Genetic Diagnostics. Top assignees: The Children's Hospital of Philadelphia, Decode Genetics Ehf, Icahn School of Medicine at Mount Sinai. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hakon Hakonarson. Retrieved from https://idiyas.com/inventor/hakon-hakonarson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 (Patent Applications = 44)

% Patents Active = 89.4

CIPO Patents = 10 (Patent Applications = 14)

EPO Patents = 24 (Patent Applications = 37)

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 81(Granted Patents)

Location History:

Reykjavic, IS (2003)
Reykjavik, IS (2005 - 2008)
Revkjavik, IS (2008)
Malvern, PA (US) (2013 - 2023)

Company Filing History:

44 out of 300

The Children's Hospital of Philadelphia

Icahn School of Medicine at Mount Sinai

patents

4. 1 out of 1

Arctic Therapeutics Hf

patent

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Genetic Variations

Asthma Treatment

ADHD Diagnosis

Autoimmune Diseases

Lymphatic Disorders

Neurodegenerative Disorders

Attention Deficit Disorder

Tourette Syndrome

Autism Treatment

Cystatin C Amyloid

Eosinophilic Esophagitis

Inflammatory Bowel Disease

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12582637 - Topical formulation for intradermal application and uses thereof (2026-03-24),

2. 12545948 - IDENTIFICATION OF NOVEL LOCI IN ASTHMA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA (2026-02-10),

3. 12509729 - COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS (2025-12-30),

4. 12365946 - Compositions and methods for the diagnosis and treatment of lymphatic system disorders (2025-07-22),

5. 12139762 - Association of genetic variations to diagnose and treat attention-deficit hyperactivity disorder (ADHD) (2024-11-12),

6. 12121514 - Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome (2024-10-22),

7. 12091708 - Compositions and methods targeting the Th2 pathway for the treatment of asthma (2024-09-17),

8. 11806341 - Methods of diagnosing and treating anxiety disorder (2023-11-07),

9. 11806340 - Methods of diagnosing and treating conduct disorder (2023-11-07),

10. 11779577 - Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder (2023-10-10),

11. 11718877 - Methods for use in the diagnosis of autoimmune diseases (2023-08-08),

12. 11684617 - Methods of diagnosing and treating ADHD in biomarker positive subjects (2023-06-27),

13. 11591656 - Association of genetic variations to diagnose and treat attention-deficit hyperactivity disorder (ADHD) (2023-02-28),

14. 11499194 - CXR4 as a susceptibility locus in juvenile idiopathic arthritis (JIA) and methods of use thereof for the treatment and diagnosis of the same (2022-11-15),

15. 11401553 - Compositions and methods for the diagnosis and treatment of lymphatic system disorders (2022-08-02),

Title: Hakon Hakonarson: Innovator in ADHD Research

Introduction

Hakon Hakonarson, based in Malvern, PA, is a prominent inventor known for his significant contributions to research on attention-deficit hyperactivity disorder (ADHD). With an impressive portfolio of 43 patents, he has pioneered various methods and compositions that aim to improve the diagnosis and treatment of ADHD and related conditions.

Latest Patents

Among Hakonarson's latest innovations is a patent focusing on the association of genetic variations to diagnose and treat ADHD. This work provides new compositions and methods aimed at enhancing the detection and management of the disorder. Additionally, he has developed a patent on nonselective metabotropic glutamate receptor activators for the treatment of ADHD, 22q deletion and/or duplication syndrome, and associated comorbidities. This application discusses the use of such activators, like fasoracetam, on individuals with specific genetic alterations in the metabotropic glutamate receptor (mGluR) network gene.

Career Highlights

Hakonarson has held significant positions in reputable organizations that underline his impact in the field of genetic research. Notably, he has worked at The Children's Hospital of Philadelphia, where he contributed to groundbreaking studies and clinical advancements. Additionally, his tenure at Decode Genetics Ehf has further solidified his standing as a leading expert in genetic research linked to ADHD.

Collaborations

Throughout his career, Hakonarson has collaborated with esteemed colleagues, including Charlly Kao and Jonathan Paul Bradfield. These collaborations have facilitated the exchange of innovative ideas and research, enhancing the potential for advancements in ADHD treatment and understanding.

Conclusion

Hakon Hakonarson's contributions to the fields of genetics and ADHD research exemplify the powerful intersection of innovation and healthcare. His extensive patent portfolio not only reflects his commitment to advancing medical science but also highlights the potential for future breakthroughs that could transform the way ADHD is diagnosed and treated.

Profile summary based on public USPTO records.